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Table 1
Cells/mm3 All Patients TFM/Cy FluBu2/ATG CB P value
CD3- D30 284 376 277 16.5 <0.0001
D100 518 598.5 1159 125 <0.0001
1 year 669 744.5 690 244 0.13
CD4- D30 100 111 129.5 4 <0.0001
D100 175 189 276 53 <0.0001
1 year 251 293 269 141 0.08
CD19- D30 2 1 8 2 <0.0001
D100 41.5 24 73.5 273.5 0.03
1 year 184.5 204 96 925 0.01
T-reg D30 14 16 10.5 2 0.06
D100 18.5 20 29.1 5.5 0.13
1 year 22 21.5 38 12.5 0.14
NK-cells- D30 136 29 205 264 <0.0001
D100 150 110 201 269 0.001
1 year 143 132.5 148 166 0.53
IgA- D30 59 46 147 54 <0.0001
D100 60.5 26 131 33.5 <0.0001
1 year 58 51 45 77.5 0.13
IgG- D30 593 534 763 548 0.01
D100 612 494 656 592 0.45
1 year 760 784 742 878 0.46
IgM- D30 29 23.1 58.6 28.1 0.01
D100 30.2 17.0 80.2 58.9 <0.0001
1 year 52.2 42.2 53.8 81.1 0.25
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170S168Conclusion: Our results show that CB allo-SCT with TFM/
ATG conditioning was associated with faster recovery of NK-
cells and CD19 cell; however with delayed recovery of T-
lymphocyte subsets. Recovery of T-lymphocyte subsets was
almost comparable in both arms receiving allo-SCT with RIC
regimen regardless of the use of post-tx Cy vs ATG. FluBu2/
ATG regimen was associated with faster recovery of serum
Ig’s in the early post-transplant period.
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Umbilical cord blood transplantation (UCBT) is characterized
by delayed immune reconstitution even with the use of
double unit UCBT (dUCBT). Previously we reported that
reconstitution of thymopoiesis, as determined by assessment
of T-cell receptor excision circles (TRECs), plays a critical role
in the clearance of CMV viremia and is associated with
improved overall survival in dUCBT recipients. We also
determined that recovery of speciﬁc T-cell subsets after
dUCBTcorrelates with serum levels of Interleukin 7 (IL-7) and
Stem Cell Factor (SCF). Here we investigated whether thymic
reconstitution depends on IL-7 and SCF and examined the
prognostic role of TRECs, IL-7 and SCF levels in clinical out-
comes after dUCBT. Fifty-two patients with hematologic ma-
lignancies received dUCBT following either reduced-intensity
(ﬂudarabine, melphalan and antithymocyte globulin) or
myeloablative conditioning (ﬂudarabine, cyclophosphamide
and TBI). GvHD prophylaxis was tacrolimus in combination
with sirolimus ormycophenolatemofetil. The incidence rates
of grade II-IV acute GvHD and chronic GvHD were 15.4% and
29% respectively. The 5-year cumulative incidence of relapse,non-relapse mortality (NRM), progression-free survival (PFS)
and overall survival (OS) were 43%, 31%, 26%, and 41%
respectively. During the ﬁrst 3 months after dUCBT, TRECs
remained undetectable or extremely low but, at 6 months,
69.7% of patients had detectable levels. At one year, TRECs
were detectable in 86.6% of patients with a median value of
2404 copies/ug DNA. Serum levels of IL-7 increased 3-fold
from baseline by 1 month after dUCBT, remained elevated
through the ﬁrst 3 months, and gradually declined to pre-
transplant levels by1 year. SCF levels peakedat 2months after
dUCBT and gradually declined thereafter. We observed a sta-
tistically signiﬁcant inverse correlationbetweenTRECsand IL-
7 (p¼0.036) or SCF (p<0.02) serum levels at various time
points after dUCBT, suggesting that uptake of these two cy-
tokines by thymocytes may lead to their differentiation into
TREC-containing Recent Thymic Emigrants (RTE). In multi-
variable analysis, higherTREC levels independentlycorrelated
with improved OS (p¼0.02) and lower NRM (p¼0.008).
Conversely, higher levels of SCFand IL-7 correlatedwith lower
OS (p¼0.005andp<0.0001). Furthermore, SCF level predicted
NRM (p¼0.003), whereas serum IL-7 level independently
predicted cGvHD (p¼0.03). Taken together, our ﬁndings sug-
gest that high IL-7 and SCF serum levels are associated with
delayed thymic reconstitution and may predict adverse out-
comes after dUCBT, including cGvHD, NRM and OS.
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Figure. Logistic dynamics of lymphoid recovery following SCT. Three patterns are observed, corresponding to high, pattern A, intermediate, pattern B and slow
growth rate, pattern C.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S169Background: Post-transplant cyclophosphamide (PTCy) is
increasingly used as a GVHD prophylaxis after alternative
donor hematopoietic cell transplant (HCT). We sought to
characterize outcomes, chimerism and immune reconstitu-
tion (IR) after PTCy following myeloablative/reduced in-
tensity (MA/RIC) peripheral blood stem cell (PBSC) HCT and
compare these to matched related donor HCT (MRD).
Methods: We identiﬁed 107 patients who received MA/RIC
T-cell replete allogeneic PBSC HCT between July 2012 and
July 2014 at our center. A total of 39 patients underwentMRD
without PTCy and 68 patients received PTCy after HLA
matched unrelated donor (MUD), mismatched unrelated
donor (mMUD), or haploidentical (haplo) HCT. The prepar-
ative regimens were ﬂudarabine(FLU)/busulfan (BU), FLU/TBI
10-12 Gy or CY/TBI 12 Gy. The GVHD prophylaxis was PTCy
50 mg/m2 on day +3 (days +3 and +4 for haplo), tacrolimus
on day +5 to +100 and MMF on day +5 to day +35. After
transplant, peripheral blood short tandem repeat donor
chimerism of CD3 and CD15 cells and ﬂow cytometry IR
panel were done on days +30, +60, +100 +180, +270 and 1
year.
Results: The PTCy group (n ¼68) were MUD, mMUD, and
haplo (n¼44, 12, and 12). Patients had hematological ma-
lignancies except 1 SAA and 1 porphyria. Median age was 50
years (range). The median follow up of alive patients was 10
months. All patients engrafted except one haplo patient
(salvagedwith repeat haplo from a different donor). Absolute
neutrophil count and platelet recovery occurred after a me-
dian of 12 and 13 days respectively. Rates of acute GVHD
(grades II-IV) and extensive chronic GVHDwere 8% and 8% in
haplo vs 18% and 18% in MUD/mMUD. One-year relapse was
8% in haplo vs 30% in MUD/mMUD. One-year non-relapse
mortality (NRM)was 17% and 25% in haplo andMUD/mMUD.
Therewas no difference in disease-free survival (DFS) [55% vs
50%] and overall survival (OS) [73% vs 62%] between haplo
and MUD/mMUD.
We compared these 2 groups with the MRD HCT (n: 39)
that did not receive PTCy. DFS, OS and NRM were similar
among the 3 groups. On day +30, CD15 donor chimerismwas
100% in the 3 groups. Day +30 CD3 donor chimerism was
higher in haplo vs MRD and MUD (P¼0.004). Day +60
chimerism did not differ among the 3 groups. T cell count
normalized by day +90 (MRD); +180 (MUD/mMUD); and
+270 (haplo) with faster recovery on day +30 in the MRD
group (p ¼ 0.006). Robust CD4 recovery was noted in the
haplo group on day +180. NK cell recovery was similar in all
groups, but tended to be higher on day +270 in haplo.
Conclusion: PTCy with MA/RIC PBSC transplant is feasible
with favorable outcome. PTCy does not compromise
donor chimerism. Lower relapse among haplo patients
may be attributed to early donor chimerism. T cell re-
covery after PTCy was delayed but did not impact NRM or
survival.210
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conditioning (RIC) regimens is controversial because of
impairment in post-transplant immune reconstitution. In this
abstract the dynamics of immune recovery following RIC
regimen for either MRD or URD SCT in a randomized phase II
clinical trial are reported. Conditioning was with Thymoglo-
bulin (ATG 5.1 (n¼19) or ATG 7.5 (n¼22) mg/kg) and 450 cGy
TBI; GVHD prophylaxis was with tacrolimus and mycopheno-
late mofetil. The patients were heavily pretreated, and had
relapsed or high-risk hematological malignancies. Two-year
survivalwas71 and61% respectively in theATG5.1 andATG7.5
arms, with corresponding relapse rates of 21 and 46% (P¼ NS),
day 100 mortality was zero. Lineage speciﬁc chimerism and
lymphocyte subsets were measured at 4, 8, and 12 weeks and
asclinically indicated. Therewasa trend towards superior Tcell
engraftment in the ATG5.1 arm,with respect to both CD3+ cell
chimerismduringeachof theﬁrst 3months (0,1, 2*vs.7, 9,19%*
recipient chimerism; *P¼0.024), and donor derived (dd) CD3+
cells (93, 106, 92* vs. 214, 577, 405 mL-1 *; *P¼0.031). The
ddCD3+ cell counts for each individual over time was plotted
and the polynomial equation describing the curve determined
in27 patients. The derivative of this curve at day 45yielded the
instantaneous rateof changeofddCD3+cells at that time. In the
ten patients where this value was <1.5, relapse and donor
lymphocyte infusions (DLI) were more frequent (P¼0.01 and
0.0033 respectively). Because ddCD3 data was available for
limited time points, absolute lymphocyte counts (ALC, mL-1) for
each individual were plotted over time to accurately model
immune reconstitution kinetics. Similar to population growth
models, lymphocyte recovery following SCT occurred as a
